iTeos Therapeutics Inc.: iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

- Entered into landmark collaboration with GSK for EOS-448/GSK4428859A; began dosing patients in Jemperli (dostarlimab-gxly) and EOS-448 combination trial and announced plans to initiate multiple registration-directed

Related Keywords

Louisiana ,United States ,New Orleans ,Gosselies ,Waals Gewest ,Belgium ,American ,Michel Detheux ,Bryan Baker ,Teos Therapeutics Inc ,Nasdaq ,Exchange Commission ,Trademark Office ,American Society Of Hematology ,Development Rd Expenses ,American Association For Cancer Research ,Late Breaking Research ,Bristol Myers Squibb ,Fred Hutchinson Cancer Research Center ,Teos Therapeutics ,American Society ,Annual Meeting ,American Association ,Cancer Research ,Investigational New Drug Enabling ,Breaking Abstract Title ,Molecular Therapeutics ,Full Year ,Private Securities Litigation Reform Act ,United States Patent ,Annual Report ,Iteos ,Herapeutics ,Reports ,Fourth ,Quarter ,Bull ,Ear ,021 ,Financial ,Results ,Rovides ,Business ,Update ,